Blueprint Medicines Corp (NASDAQ:BPMC) CEO Jeffrey W. Albers sold 20,000 shares of the stock in a transaction on Monday, November 5th. The shares were sold at an average price of $63.49, for a total transaction of $1,269,800.00. Following the completion of the sale, the chief executive officer now directly owns 20,000 shares of the company’s stock, valued at $1,269,800. The sale was disclosed in a filing with the SEC, which is available through the SEC website.
Shares of Blueprint Medicines stock opened at $60.22 on Friday. The company has a quick ratio of 10.05, a current ratio of 10.05 and a debt-to-equity ratio of 0.03. Blueprint Medicines Corp has a fifty-two week low of $57.44 and a fifty-two week high of $109.00. The firm has a market capitalization of $2.71 billion, a price-to-earnings ratio of -15.36 and a beta of 1.46.
Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings data on Tuesday, October 30th. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.57) by ($0.09). Blueprint Medicines had a negative net margin of 455.15% and a negative return on equity of 36.72%. The business had revenue of $1.10 million during the quarter, compared to analyst estimates of $1.87 million. During the same quarter in the prior year, the company posted ($0.96) EPS. The company’s quarterly revenue was down 86.4% compared to the same quarter last year. On average, equities research analysts expect that Blueprint Medicines Corp will post -5.25 earnings per share for the current fiscal year.
Hedge funds have recently made changes to their positions in the company. Bank of Montreal Can acquired a new position in shares of Blueprint Medicines in the 2nd quarter valued at $154,000. grace capital acquired a new position in shares of Blueprint Medicines in the 2nd quarter valued at $171,000. Jane Street Group LLC acquired a new position in shares of Blueprint Medicines in the 2nd quarter valued at $206,000. NumerixS Investment Technologies Inc raised its stake in shares of Blueprint Medicines by 750.0% in the 2nd quarter. NumerixS Investment Technologies Inc now owns 5,100 shares of the biotechnology company’s stock valued at $311,000 after buying an additional 4,500 shares in the last quarter. Finally, Public Employees Retirement Association of Colorado raised its stake in shares of Blueprint Medicines by 56.7% in the 3rd quarter. Public Employees Retirement Association of Colorado now owns 4,718 shares of the biotechnology company’s stock valued at $368,000 after buying an additional 1,708 shares in the last quarter. Institutional investors own 99.73% of the company’s stock.
A number of brokerages have weighed in on BPMC. BidaskClub raised shares of Blueprint Medicines from a “sell” rating to a “hold” rating in a report on Saturday, September 1st. Cowen reissued a “buy” rating on shares of Blueprint Medicines in a report on Wednesday, August 1st. ValuEngine raised shares of Blueprint Medicines from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 2nd. Wedbush reissued an “outperform” rating and issued a $101.00 price target on shares of Blueprint Medicines in a report on Monday, October 22nd. Finally, Leerink Swann began coverage on shares of Blueprint Medicines in a report on Tuesday, September 25th. They issued an “outperform” rating and a $105.00 price target for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $97.14.
WARNING: This piece was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international trademark and copyright law. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/11/10/blueprint-medicines-corp-bpmc-ceo-sells-1269800-00-in-stock.html.
Blueprint Medicines Company Profile
Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V mutations, that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors and systemic mastocytosis; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.
Further Reading: How to Invest in the Dividend Aristocrat Index
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.